Le rein de l'enfant face à la chimiothérapie

Revue Medicale de la Suisse Romande

Volumn 116, Issue 12, 1996, Pages 985-993

  Cachat, François ^a   Guignard, Jean Pierre ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; SEMUSTINE;

CANCER CHEMOTHERAPY; CHILD; HUMAN; NEPHROTOXICITY; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARBOPLATIN; CHILD; CISPLATIN; GLOMERULAR FILTRATION RATE; HUMANS; IFOSFAMIDE; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; METHOTREXATE; MITOMYCIN; SEMUSTINE;

EID: 3342939222     PISSN: 00353655     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Terracini B., Pastore C., Zunlo M.G.: Late deaths and secondary primary malignancies among long term survivors of childhood cancer: an Italian multicentre study. Eur. J. Cancer. Clin. Oncol., 23: 499-504, 1987.
2. Long-Term survivors of childhood cancer. Pediatrician, 18: 2-96, 1987.
3. Blachley J.D., Hill J.B.: Renal and electrolyte disturbances associated with cisplatin. Ann. Int. Med., 95: 628-632, 1981.
4. Bianchetti M.G., Kanaka C., RidolfiLüthy A. et al.: Persisting renotubular sequelae after cisplatin in children and adolescents. Am. J. Nephrol., 11:127-130, 1991.
5. Fjeldborg P., Sorensen J., Helkjaer P.E.: The long-term effect of cisplatin on renal function. Cancer, 58: 2214-2217, 1986.
6. Dobyan D.C.: Long-term consequences of cis-platinum-induced renal injury: a structural and functional study. Anat Rec., 212: 239-245, 1985.
7. Yasumasu T., Ueda T., Uozumi J. et al.: Ultrastructural alteration and DNA synthesis of renal cell nuclei following cisplatin or carboplatin injection in rats. J. Pharm. Pharmacol., 44: 885-887, 1992.
8. Guinee D.G., Van Zee B., Houghton D.C.: Clinicaly silent progressive renal tubulointerstitial disease during cisplatin chemotherapy. Cancer, 71: 4050-4054, 1993.
9. Treskes M. Van der Vijgh W.J.F.: WR2721 as a modular of cisplatin- and carboplatin- induced side effects in comparison with other chemoprotectives agents: a molecular approach. Cancer Chemother. Pharmacol., 33: 93-106, 1993.
10. Lieberthal W., Triaca V., Levine J.: Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs necrosis. Am. J. Physiol. 270 (Renal Fluid Electrolyte Physiol 39): F700-F708, 1996.
11. Daugaard A., Abildgaard U., Holstein-Rathlou N.H. et al.: Acute effect of cisplatin on renal hemodynamics and tubular function in dog kidneys. Renal Physiol., 9: 308-316, 1986.
12. Al-Sarraf M., Fletcher W., Oishi N. et al.: Cisplatinum hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group Study. Cancer Treat. Rep., 66: 31-35, 1982.
13. Semama D., Heumann C. and Guignard J.-P.: Protection from hypoxemic renal dysfunction by verapamil and manganese in the rabbit. Life Science, 56: 231-239, 1994.
14. Skinner R., Pearson A.D.J., Coulthard M.G. et al.: Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemother. Pharmacol., 28: 81-92, 1991.
15. Cornelisen T.L., Reed E.: Nephrotoxicity and hydratation management for cisplatin, carboplatin, and ormaplatin. Gynecol. oncol., 50: 147-158, 1993.
16. Boss J. Welslau U., Ritter J. et al.: Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother. Pharmacol., 28: 455-460, 1991.
17. Fukuoka M., Negoro S., Masuda N. et al.: Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J. Cancer Res. Clin. Oncol., 117:473-478, 1991.
18. Mohrmann M., Ansorge S., Schmich U. et al.: Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture. Pediatr. Nephrol., 8: 157-163, 1994.
19. Rossi R., Danzebrink S., Hillebrand D. et al.: Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med. Pediatr. Oncol., 22: 27-32, 1994.
20. Dumas R.: Rachitisme vitaminorésistant dans le syndrome de De ToniDebré-Fanconi. In: Métabolisme phosphocalcique normal et pathologique chez l'enfant, par Garabedian M., David L., Dumar R. et Mallet E., éd. Médecine-Sciences Flammarion, Paris, pp. 98-101, 1993.
21. Hanquinet S., Wouter M., Devalck C. et al.: Increased renal parenchymal echogenicity in ifosfamide-induced renal Fanconi syndrome. Med. Pediatr. Oncol., 24: 116-118, 1995.
22. Izquierdo R., Leinung M.: Hyponatremia secondary to administration of ifosfamide (letter). Eur. J. Cancer, 29: 2072-2073, 1993.
23. Culine J.S., Ghosn N., Droz J.-P.: Inappropriate antidiuretic hormone secretion induced by ifosfamide (letter). Eur. J. Cancer, 26: 922, 1990.
24. O'Marcaigh A.S., Johnson C.M., Smithson W.A. et al.: Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2. Mayo Clinic Proc., 71: 161-165, 1996.
25. Widemann B., Hetherington M.L, Murphy R.F., Balis F.M., Adamson P.C.: Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer, 76:521-526, 1995.
26. Abelson H.T., Garnick M.B.: Renal failure induced by cancer chemotherapy. In Riesselbach R.E. and Garnick M.B. (eds), Cancer and the Kidney. Philadelphis, Lea & Febiger, pp. 769-813, 1982.
27. Link D.A., Fosburg M.T., Ingelfinger J.R.: Renal toxicity of high dose methotrexate. Pediatr. Res., 10: 455, 1976.
28. Harmon W.E.: Chronic renal failure in children treated with methyl CCNU. N. Engl. J. Med., 300:1200-1203, 1979.
29. Schacht R.G.: Nephrotoxicity of nitrosureas. Cancer, 48: 1328-1334, 1981.
30. Price T.M.: Renal failure and hemolytic anemia associated with mitomycin C. Cancer, 55: 51-56, 1985.
31. Koduri P.R.: Alkali therapy, hyperphosphatemia, and acute tumor lysis syndrome. Med. Pediatr. Oncol., 26: 73, 1996.
32. Becker B.N., Fall P., Hall C. et al.: Rapidly progressive acute renal failure fue to acyclovir: case report and review of the literature. Am. J. Kidney Dis., 22: 611-615, 1993.
33. Rieselbach R.E., Garnick M.B.: Cancer and the kidney, Lea & Febiger, Philadelphia, p. 496, 1982.